Introduction
============

Invasive candidiasis (IC) is increasing in prevalence, especially among immunocompromised patients and those with serious underlying disease. In addition, mortality from IC remains high.[@b1-idr-11-155] *Candida tropicalis* and *Candida glabrata* are two major pathogenic non-*albicans Candida* species. *C. glabrata* is the second most common cause of candidemia in Europe and America, while *C. tropicalis* has become the first and second leading cause of IC in India and the People's Republic of China, respectively.[@b1-idr-11-155]--[@b3-idr-11-155] These species are notable for their resistance or reduced susceptibility to azole antifungal agents.[@b4-idr-11-155],[@b5-idr-11-155]

As such, the echinocandins are increasingly used as first-line therapy for IC, because of their good efficacy and safety profiles.[@b4-idr-11-155],[@b6-idr-11-155] However, reduced susceptibility and resistance among *Candida* species to these agents has also been noted, linked to mutations within specific hotspot (HS) regions of the *Candida FKS* genes.[@b7-idr-11-155],[@b8-idr-11-155] The emergence of echinocandin resistance has been most concerning for *C. glabrata*, especially in North America, while echinocandin resistance in other *Candida* species and in other geographical regions remains more uncommon.[@b6-idr-11-155],[@b9-idr-11-155]

In the China Hospital Invasive Fungal Surveillance Net (CHIF-NET) 2013 program, one *C. tropicalis* and *C. glabrata* isolate each was found to be resistant to all three licensed echinocandin agents,[@b3-idr-11-155],[@b10-idr-11-155] being the first pan-echinocandin-resistant isolates identified in the country. Here, we report the clinical features of the patients affected by these pan-echinocandin-resistant strains. We also determined the mechanism of resistance in the isolates.

Case presentation
=================

Case 1: Infection with echinocandin-resistant *C. glabrata*
-----------------------------------------------------------

On September 27, 2012, a 46-year-old male was admitted to the Department of Pancreatic Surgery in a hospital in the Northeast region of the People's Republic of China with fever and an abdominal wound infection ([Table 1](#t1-idr-11-155){ref-type="table"}). He had experienced a right hepatectomy, subtotal gastrectomy, transverse colon loop ostomy, and right thoracic cavity drainage and closure 38 days prior in another hospital owning to severe trauma. He was immunocompetent. Before admission, the patient had received imipenem therapy for 10 days because of *Escherichia coli* bacteremia, but there was no history of exposure to antifungal agents.

On day 4 of admission, the local laboratory reported growth of *C. glabrata* in the ascitic fluid of the patient collected on day 2; however, antifungal susceptibility testing was not performed. Fluconazole therapy 200 mg/d was initiated immediately on day 4 for 23 days duration. No other cultures were positive for fungi. The patient made good clinical recovery and was discharged on October 24 (day 27).

Case 2: Echinocandin-resistant *C. tropicalis*
----------------------------------------------

On May 10, 2013, a 69-year-old female was admitted to the intensive care unit of a hospital in the Middle region of the People's Republic of China with severe asthma and pulmonary infection ([Table 1](#t1-idr-11-155){ref-type="table"}). She suffered from severe coronary disease, underwent aortic valve replacement 1 month prior in another hospital, and had since developed multiple organ dysfunction. A previous sputum culture within the last 30 days was positive for *Acinetobacter baumannii* and *Candida albicans*. From day 1 of admission, she received meropenem 3 g/d for 22 days and micafungin 100 mg/d for 18 days.

On day 8 of admission, a chest tube was placed in the left chest wall for drainage of a pleural effusion from unresolved pneumonia. On day 33, *C. tropicalis* was cultured from the pleural drainage fluid. The local laboratory performed antifungal susceptibility testing of the isolate by the disk diffusion method,[@b11-idr-11-155] but only for fluconazole, and reported a "susceptible" result. Voriconazole therapy (200 mg/d) was initiated and continued till day 99 of admission when the patient passed away from heart failure.

Materials and methods
=====================

Ethics statement
----------------

Written informed consent to publish their case details was obtained from the patient, or next of kin where the patient was unable to consent. The Human Research Ethics Committee of Peking Union Medical College Hospital has provided permission to publish this report (S-628).

Detection of the pan-echinocandin-resistant *Candida* isolates from CHIF-NET national surveillance
--------------------------------------------------------------------------------------------------

CHIF-NET was established as a nationwide surveillance program in the People's Republic of China to monitor the trends in the epidemiology of invasive yeast infections and to provide up-to-date susceptibility data on antifungal agents.[@b2-idr-11-155],[@b3-idr-11-155],[@b10-idr-11-155] CHIF-NET 2013 comprised the fourth consecutive surveillance year of the program, held from August 1, 2012 to July 31, 2013. Generally, all yeast isolates collected in CHIF-NET 2013 were forwarded to the central laboratory, the Department of Clinical Laboratory, Peking Union Medical College Hospital. Confirmation of species identification was carried out by an algorithm of matrix-assisted laser desorption/ionization-time of flight mass spectrometry (Vitek MS; bioMérieux, Marcy l'Etoile, France) supplemented with rDNA internal transcribed spacer (ITS) sequencing.[@b12-idr-11-155] The in vitro susceptibility to nine antifungal drugs, including three echinocandins (caspofungin, micafungin, and anidulafungin), amphotericin B, and 5-flucytosine, was determined using Sensititre Yeast-One™ YO10 methodology (Sensititre; Thermo Scientific, Cleveland, OH, USA) following the manufacturer's instructions. Current available species-specific clinical breakpoint or epidemiological cut-off values were used for interpretation of results ([Table S1](#SD1-idr-11-155){ref-type="supplementary-material"}).[@b13-idr-11-155]--[@b15-idr-11-155] Only one *C. glabrata* (CHIF-NET study no. 12Z1132) and one *C. tropicalis* (study no. 13TJ350) isolate, which were isolated from the patients described above, were resistant to all the echinocandins ([Table 1](#t1-idr-11-155){ref-type="table"}).

Analysis of the *FKS* gene
--------------------------

For *C. glabrata* strain 12Z1132, sequencing of *FKS1* and *FKS2* genes was carried out as described by Zimbeck et al;[@b8-idr-11-155] sequences of *C. glabrata* strain CBS 138 (GenBank accession numbers XM_446406 and XM_448401 for*FKS1* and *FKS2*, respectively) were the wild-type (WT) reference sequences. For *C. tropicalis* strain 13TJ350, sequencing of *FKS1* gene was carried out as described by Jensen et al,[@b7-idr-11-155] with the sequence of *C. tropicalis* ATCC 750 (GenBank accession number EU676168) representing the WT reference sequence.

Nucleotide sequences
--------------------

The partial*FKS2* gene sequence of *C. glabrata* 12Z1132 and partial *FKS1* gene sequence of *C. tropicalis* strain 13TJ350 have been deposited in GenBank database, with GenBank accession numbers of MF667536 and MF667537, respectively.

Results
=======

Echinocandin-resistant isolates
-------------------------------

In CHIF-NET 2013, 2,687 yeast isolates were collected from 48 hospitals in the People's Republic of China where *C. tropicalis* (413 isolates, 15.4%) and *C. glabrata* sensu stricto (254 isolates, 9.5%) were the third and fourth most common species. However, only *C. tropicalis* isolate 13TJ350 and *C. glabrata* isolate 12Z1132 were echinocandin-resistant. These were the first pan-echinocandin-resistant*C. tropicalis* and *C. glabrata* isolates identified in the People's Republic of China.[@b3-idr-11-155],[@b10-idr-11-155]

Antifungal susceptibilities
---------------------------

*C. glabrata* strain 12Z1132 was resistant to all three echinocandin agents, with minimum inhibitory concentrations of ≥8 µg/mL ([Table 1](#t1-idr-11-155){ref-type="table"}). *C. tropicalis* strain 13TJ350 was also pan-echinocandin resistant, with minimum inhibitory concentrations of 4 µg/mL, 2 µg/mL, and 2 µg/mL to caspofungin, micafungin, and anidulafungin, respectively ([Table 1](#t1-idr-11-155){ref-type="table"}). Both strains were susceptible or of WT phenotype to 5-flucytosine, amphotericin B, and four azoles tested, except for *C. glabrata* strain 12Z1132 which was susceptible in a dose-dependent manner to fluconazole ([Table 1](#t1-idr-11-155){ref-type="table"}).

Analysis of *FKS* genes
-----------------------

A mutation leading to the amino acid substitution S80P was found in HS1 region of the *FKS1* gene of *C. tropicalis* strain 13TJ350*.* However, no amino acid substitution was detected in HS regions of *FKS1* and *FKS2* genes in *C. glabrata* strain 12Z1132. Instead, there was a mutation leading to the amino acid substitution E655K adjacent to HS1 region of the *FKS2* gene.

Discussion
==========

Because there are only a few classes of antifungal agents, for example, the azoles, echinocandins and polyenes, in clinical use, options for antifungal therapy are relatively limited. Facing the challenges posed by azole resistance, echinocandins have become the preferred therapy for IC.[@b4-idr-11-155],[@b6-idr-11-155] Overall, resistance to the echinocandins appears to be uncommon. From a recent global surveillance report, echinocandin susceptibility rates were over 95% for *C. albicans* as well as for the more commonly encountered non-*albicans Candida* species.[@b16-idr-11-155] However, since the first report of reduced susceptibility to caspofungin in *C. albicans* in 2004,[@b17-idr-11-155] echinocandin resistance among *Candida* isolates has been increasingly identified among different *Candida* species, raising global concern.[@b4-idr-11-155],[@b5-idr-11-155],[@b16-idr-11-155]

Of the three licensed echinocandin agents, caspofungin and micafungin were approved for marketing by the China Food and Drug Administration in 2006, while no commercial brand of anidulafungin drug has been approved for use in the People's Republic of China, until now. Although the use of echinocandin drugs has increased since 2006, the prevalence of echinocandin-resistant strains is not known. At the inception of the first CHIF-NET study (2009), no clinical laboratory was routinely performing antifungal susceptibility testing for echinocandins, underscoring lack of data for this important phenomenon.

Specifically, at the initial stage of the CHIF-NET study, the focus of surveillance involved drug susceptibility only to fluconazole and voriconazole and by using diffusion methods.[@b2-idr-11-155] To overcome the lack of data on echinocandin susceptibility, in 2015, the CHIF-NET study group initiated surveillance of echinocandin susceptibilities on common non-*albicans Candida* species. In the 3-year review, only one*C. glabrata* strain resistant to anidulafungin (0.4%) was detected, while no strain was found to be resistant to caspofungin or micafungin.[@b2-idr-11-155] Since then, the first pan-echinocandin-resistant *Candida* strains in the People's Republic of China have been identified by Fan et al[@b3-idr-11-155] and Hou et al[@b10-idr-11-155] in the 5-year review of *C. glabrata* and *C. tropicalis* species, respectively.

Of note, most echinocandin resistance in *Candida* species worldwide have been documented in *C. glabrata*.[@b4-idr-11-155],[@b5-idr-11-155],[@b16-idr-11-155] In addition, the prevalence of echinocandin resistance has varied with geographic region: echinocandin-resistant *C. glabrata* is more common in North America (7%--10%) than in other continents (0%--2%).[@b16-idr-11-155] Echinocandin resistance is typically associated with prior antifungal drug exposure.[@b4-idr-11-155],[@b9-idr-11-155],[@b18-idr-11-155] However, in our patient with infection due to an echinocandin-resistant *C. glabrata*, no previous antifungal use was evident. The infection was thought to be acquired after the patient's abdominal operation, supporting the notion that, even without typical risk factors,[@b18-idr-11-155] patients may become infected by echinocandin-resistant strains.

Echinocandin resistance in *C. tropicalis* appears to be uncommon (\<1%).[@b3-idr-11-155],[@b6-idr-11-155],[@b14-idr-11-155],[@b16-idr-11-155] Reports of infections caused by such strains have included three cases of breakthrough candidemia in allogeneic stem cell recipients,[@b19-idr-11-155] and a case of candidal esophagitis in a patient with acute myelogenous leukemia.[@b20-idr-11-155] Compared with published reports, our patient (patient 2) had exposure to at least one echinocandin, but the patient was not immunosuppressed.

It is well established that mutations in the *FKS* gene account for echinocandin resistance and that their presence is linked with failure of echinocandin therapy.[@b4-idr-11-155],[@b7-idr-11-155],[@b21-idr-11-155] Although other resistant mechanisms, for example, alterations in the mismatch repair gene *msh2*, have also been reported, their role in conferring resistance is less certain.[@b9-idr-11-155] In *C. albicans* and *C. tropicalis*, amino acid substitutions associated with resistance have mainly been documented in two HS regions (HS1 and HS2) of the *FKS1* gene, while in *C. glabrata*, these mutations are in homologous regions of *FKS1* and *FKS2* genes.[@b4-idr-11-155],[@b7-idr-11-155],[@b21-idr-11-155] In the present study, the S80P substitution was found in HS1 region of the *FKS1* gene in *C. tropicalis* strain 13TJ350; this substitution has been linked to echinocandin resistance in *C. tropicalis.*[@b7-idr-11-155] Although there was no amino acid substitution in HS regions of the *FKS1* and *FKS2* genes in *C. glabrata* strain 12Z1132, the E655K substitution was identified upstream to *FKS2* gene HS1 region compared with the WT strain. However, as a limitation of the study, the correlation between the novel E655K substitution identified in the *C. glabrata* isolate and the strain's resistance phenotype remains to be confirmed.

The emergence of multidrug resistant *Candida* isolates, for example, isolates resistant to both azoles and echinocandins that occurred in *C. glabrata*, has also been a concern.[@b4-idr-11-155],[@b5-idr-11-155] Fortunately, both our pan-echinocandin-resistant *Candida* isolates were not resistant to any of the azoles tested. Although the *C. tropicalis* infected patient finally passed away because of poor health, the *C. glabrata* infected patient exhibited good clinical response to fluconazole treatment. Importantly, since the writing of this report, an additional isolate of *C. glabrata* resistant to all azoles and all echinocandins has been identified.[@b10-idr-11-155] This emergence of multi class drug resistance signals the need for increased vigilance by clinicians and scientists alike.

Conclusion
==========

In conclusion, we describe the clinical presentation of the first patients with IC caused by pan-echinocandin-resistant*C. tropicalis* and *C. glabrata* isolates. Taking the rapid increase of azole resistance in these two species into account,[@b3-idr-11-155],[@b10-idr-11-155] the emergence of echinocandin resistance will pose challenges for management of patients with IC in the People's Republic of China.

Supplementary materials
=======================

###### 

CBPs and ECVs used in the present study

  Antifungal agents   *Candida tropicalis*   *Candida glabrata*                                                 
  ------------------- ---------------------- -------------------- ----- ---- ----- ------- ----- ------ ------- ------
  Fluconazole         ≤2                     4                    --    ≥8   --    --      ≤32   --     ≥64     --
  Voriconazole        0.125                  0.125--0.5           --    ≥1   --    --      --    --     --      2
  Itraconazole        --                     --                   --    --   1     --      --    --     --      4
  Posaconazole        --                     --                   --    --   2     --      --    --     --      4
  Caspofungin         ≤0.25                  --                   0.5   ≥1   --    ≤0.12   --    0.25   ≥0.5    --
  Micafungin          ≤0.25                  --                   0.5   ≥1   --    ≤0.06   --    0.12   ≥0.25   --
  Anidulafungin       ≤0.25                  --                   0.5   ≥1   --    ≤0.12   --    0.25   ≥0.5    --
  5-Flucytosine       --                     --                   --    --   0.5   --      --    --     --      0.25
  Amphotericin B      --                     --                   --    --   2     --      --    --     --      2

**Abbreviations:** CBP, clinical breakpoint; ECV, epidemiological cut-off value; S, susceptible; SDD, susceptible dose-dependent; I, intermediate; R, resistant.
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###### 

Clinical features of two patients with echinocandin-resistant candidiasis and in vitro susceptibilities of two isolates

  Characteristics                                           *Candida glabrata* patient                                                                           *Candida tropicalis* patient
  --------------------------------------------------------- ---------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------
  Age (years)                                               46                                                                                                   69
  Gender                                                    Male                                                                                                 Female
  Date of admission                                         September 27, 2012                                                                                   May 10, 2013
  Department of admission                                   Department of Pancreatic Surgery                                                                     ICU
  Reason for hospital admission                             Fever and abdominal incision infection                                                               Asthma, pulmonary infection
  Underlying disease                                        Right hepatectomy, subtotal gastrectomy, transverse colon loop ostomy, right closed chest drainage   Coronary heart disease, cardiac valve replacement, multiple organ dysfunction syndrome
  CHIF-NET strain no.                                       12Z1132                                                                                              13TJ350
  Site of isolation                                         Ascitic fluid                                                                                        Left chest drainage
  Date of isolation                                         October 1, 2012                                                                                      July 18, 2013
  **Clinical status at time of positive culture**                                                                                                                
  Immunosuppressive state                                   No                                                                                                   No
  Neutropenia(\<10^9^/L)                                    No                                                                                                   No
  Presence of CVC                                           No                                                                                                   No
  Broad-spectrum antibiotics                                Yes                                                                                                  Yes
  Total parenteral nutrition                                No                                                                                                   Yes
  Mechanical ventilation                                    No                                                                                                   Yes
  Surgery within 30 days                                    Yes                                                                                                  Yes
  Previous antifungal agents within 30 days                 No                                                                                                   Micafungin, 18 days
  Indwelling urinary catheter                               No                                                                                                   Yes
  **Therapy**                                                                                                                                                    
  Antifungal CVC removal                                    Not applicable                                                                                       No
  Antifungal after culture                                  Fluconazole, 200 mg/d                                                                                Voriconazole, 200 mg/d
  Outcome                                                   Recovered                                                                                            Dead
  **Antifungal susceptibilities (MIC \[mg/L\]/category)**                                                                                                        
  Micafungin                                                ≥8/R                                                                                                 2/R
  Anidulafungin                                             ≥8/R                                                                                                 2/R
  Caspofungin                                               ≥8/R                                                                                                 4/R
  Fluconazole                                               32/SDD                                                                                               2/S
  Voriconazole                                              1/WT                                                                                                 0.125/S
  Itraconazole                                              1/WT                                                                                                 0.25/S
  Posaconazole                                              2/WT                                                                                                 0.25/WT
  Amphotericin B                                            0.5/WT                                                                                               0.5/WT
  5-Flucytosine                                             ≤0.06/WT                                                                                             ≤0.06/WT

**Abbreviations:** ICU, intensive care unit; CHIF-NET, China Hospital Invasive Fungal Surveillance Net; CVC, central venous catheter; MIC, minimum inhibitory concentration; S, susceptible; SDD, susceptible dose-dependent; R, resistant; WT, wild-type.

[^1]: These authors contributed equally to this work
